The company's agreement to trade biosimilar competitors' earlier market entry in Europe for lengthier exclusivity in the U.S. does not run afoul of the Supreme Court's Actavis decision, U.S. District Judge Manish Shah ruled Monday.
June 08, 2020 at 08:20 PM
1 minute read
James Hurst, Kirkland & Ellis (Photo: Todd Winters)
The notorious 100-plus patent thicket that AbbVie Inc. planted around biologic drug Humira—and the company’s deals with competitors to enter the market—do not run afoul of federal antitrust laws.
Presented by BigVoodoo
The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
Join the Mendocino County District Attorney s Office and work in Mendocino County home to redwoods, vineyards and picturesque coastline. ...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Breaking news and trends for law firm and legal departments about the evolving federal regulations in a volatile political climate.
